<DOC>
	<DOCNO>NCT01703117</DOCNO>
	<brief_summary>Cognitive age major source disability increasingly age population . The paucity effective treatment cognitive age disorder , importantly Alzheimer 's disease instigate need research novel therapeutic possibility . Alzheimer 's disease common neurodegenerative disorder prevalence steeply increase . Glutamate-mediated excitotoxicity neuropsychiatric disorder particular Alzheimer 's disease show cause significant cerebral damage . Early effective therapeutic intervention Alzheimer 's disease critical order prevent least retard neuropathological progression lead widespread irreversible neuronal loss significant cognitive dysfunction . Riluzole , glutamate modulator agent proven safe medication yet use cognitive age disorder , test mild Alzheimer 's disease patient . Cognitive functional change along two establish vivo biomarkers , namely , Magnetic Resonance Spectroscopy ( MRS ) Fluorodeoxyglucose ( 18F ) positron emission tomography ( FDG-PET ) evaluate .</brief_summary>
	<brief_title>Riluzole Mild Alzheimer 's Disease</brief_title>
	<detailed_description>A double-blinded , randomize , placebo-controlled study perform . Forty-eight individual diagnosis mild Alzheimer 's disease 60-85 year old complete study . There two cohort 60-75 75-85 year old age-matched . All forty-eight individual donepezil , FDA approve treatment Alzheimer 's disease , dose 5mg 10mg per day least 3 month prior consent remain drug throughout study . Twenty-four mild Alzheimer 's disease patient receive riluzole another 24 receive placebo ( placebo tablet generate Rockefeller University 's pharmacy research pharmacist ) . All patient neurological evaluation neuropsychological test perform confirm meet criterion probable Alzheimer 's disease set National Institute Aging - Alzheimer 's disease Association recently revisit NINCDS-ADRDA criterion mild Alzheimer 's disease .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Riluzole</mesh_term>
	<criteria>Male female ; 60 85 year old mild Alzheimer 's disease determine neurological neuropsychological evaluation follow National Institute Aging Alzheimer 's disease Association criterion recently revisit NINCDSADRDA criterion . For mild Alzheimer 's disease , Clinical Dementia Ratings Scale ( CDR ) 0.5 1 Mini Mental State Examination ( MMSS ) 19 27 . Must donepezil ( Aricept速 ) rivastigmine ( Exelon速 ) galantamine ( Razadyne速 ) consistent dose least 2 month . Must fluent English The subject appoint previously appoint health care proxy specifically designate research consent document . ModerateSevere Alzheimer 's disease dementia determine neuropsychological test neurological evaluation . Previous riluzole treatment . MRI contraindication ( severe claustrophobia , metal implant , shunt , pacemaker , joint implant , metal valve ) . Currently take medication either evidence glutamatergic activity previous MRS evidence effect brain glutamate level discretion PI memantine , lamotrigine , lithium , opiates , bupropion , psychostimulants amphetamine methylphenidate , tricyclic antidepressant , benzodiazepine drug investigator judge might interfere study . ( subject medication may still include study however value NAA MRS utilized glutamate measurement ) . Currently user follow illicit drug : cocaine , methylenedioxymethamphetamine ( MDMA ) ( `` ecstasy '' ) , heroin opioids ( verified urine drug test ) history drug alcohol abuse within past 5 year . Serum creatinine &gt; 1.5 time upper limit normal . Abnormal liver function test ( great 2 time upper limit normal alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ; bilirubin &gt; 1.5 time upper limit normal . History brain disease include Parkinson 's Disease , severe brain trauma , seizure , history stroke , clinically significant lacunar infarct region important cognition multiple lacunes cortical infarct focal lesion clinical significance , multiple sclerosis , mental retardation , normal pressure hydrocephalus , central nervous system ( CNS ) tumor , Huntington 's disease , subdural hematoma serious neurological disorder . Uncontrolled diabetes mellitus ( Hba1c higher 7 ) chronically uncontrolled hypertension . Subject must take Namenda速 ( memantine ) least 2 month . Currently take concomitant hepatotoxic drug allopurinol , methyldopa sulfasalazine . Any unstable serious coexist medical condition ( ) include limited myocardial infarction , coronary artery disease require coronary bypass surgery , unstable angina , clinically evident congestive heart failure within 6 month prior screen visit . Current smoker user nicotinecontaining product , chew tobacco , nicotine patch gum past 2 month . Current major depression define Hamilton Psychiatric Rating Scale &gt; 18 . Participation investigational market drug device trial within 30 day prior screen visit . Significant neuropsychiatric illness bipolar disorder , schizophrenia , moderatesevere anxiety , vascular dementia , CreutzfeldtJakob dementia , HIV dementia , dementia specify disease . Subjects donepezil longer 5 year . Weight &gt; 300 pound . Lactose intolerance . Any medical social condition , opinion Investigator , might pose additional risk participant confound result study .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>Dementia</keyword>
</DOC>